{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:17:02Z","timestamp":1789096622245,"version":"build-2803163510"},"reference-count":166,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/pat.0b013e32834a9da8","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T14:39:55Z","timestamp":1317739195000},"page":"566-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular methods in diagnosis and monitoring of haematological malignancies"],"prefix":"10.1016","volume":"43","author":[{"given":"David T.","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy T.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/PAT.0b013e32834a9da8_bib0005","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2005.01.016","article-title":"Whatis targeted therapy?","volume":"23","author":"Sledge","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0010","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood.V65.5.1039.1039","article-title":"Chronic myelogenous leukemia: recent advances","volume":"65","author":"Champlin","year":"1985","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0020","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0030","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0040","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0045","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0050","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2141.2002.03508.x","article-title":"Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene","volume":"117","author":"Branford","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0060","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.2000.02042.x","article-title":"A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia","volume":"109","author":"Branford","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0065","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0070","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic asso-ciations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0075","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4065\/80.3.390","article-title":"Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00277-001-0424-5","article-title":"High reliability and sensitivity of the BCR\/ABL1 D-FISH test for the detection of BCR\/ABL rearrangements","volume":"81","author":"Pelz","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0085","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0090","first-page":"27","article-title":"Overview of real-time RT-PCR strategies for quantification of gene rearrangements in the myeloid malignancies","volume":"125","author":"Picard","year":"2006","journal-title":"Methods Mol Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0095","series-title":"Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine","first-page":"69","article-title":"Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR","author":"Branford","year":"2006"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0100","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0105","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic sig-nificance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0115","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"NEJM"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0120","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"NEJM"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0125","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0130","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0135","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0140","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0145","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0155","first-page":"1527","article-title":"Control genes in reverse transcriptase-polymerase chain reaction assays","volume":"10","author":"Lion","year":"1996","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0160","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2019real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0165","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jcla.20075","article-title":"Optimization of the PAXgene blood RNA extraction system for gene expression analysis of clinical samples","volume":"19","author":"Chai","year":"2005","journal-title":"J Clin Lab Anal"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0170","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1515\/CCLM.2008.086","article-title":"Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia","volume":"46","author":"Ernst","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1532\/LH96.05021","article-title":"Examina-tion of stability of bone marrow blood RNA in the PAXgene tube","volume":"12","author":"Yamamoto","year":"2006","journal-title":"Lab Hematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0180","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1515\/CCLM.2005.206","article-title":"Failure of the PAXgene blood RNA system to maintain mRNA stability in whole blood","volume":"43","author":"Kagedal","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11899-011-0082-1","article-title":"Chronic myelogenous leukemia: monitoring response to therapy","volume":"6","author":"Branford","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0190","first-page":"1350","article-title":"Impact of RNA stabiliza-tion on minimal residual disease assessment in chronic myeloid leukemia","volume":"90","author":"Thorn","year":"2005","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0200","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommen-dations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0205","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization ofBCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0210","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance char-acteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0215","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0220","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantita-tion ofBCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0225","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1128\/CMR.00074-09","article-title":"Validation of laboratory-developed molecular assays for in-fectious diseases","volume":"23","author":"Burd","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cccn.2003.12.034","article-title":"The truth about quality: medical usefulness and analytical reliability of laboratory tests","volume":"346","author":"Westgard","year":"2004","journal-title":"Clinica Chimica Acta"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/clinchem\/27.3.493","article-title":"A multi-rule Shewhart chart for quality control in clinical chemistry","volume":"27","author":"Westgard","year":"1981","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0240","series-title":"Myeloproliferative Disorders","first-page":"143","article-title":"Monitoring disease response","author":"Hughes","year":"2007"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0245","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1351\/pac200678010145","article-title":"The international harmonized protocol for the proficiency testing of analytical chemistry laboratories","volume":"78","author":"Thompson","year":"2006","journal-title":"Pure Appl Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0250","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/clinchem\/37.4.483","article-title":"Proficiency testing of clinical chemistry laboratories: the role of the reference laboratory","volume":"37","author":"Deming","year":"1991","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0255","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1351\/pac199365092123","article-title":"The international harmonized protocol for the proficiency testing of (chemical) analytical laboratories","volume":"65","author":"Thompson","year":"1993","journal-title":"Pure Appl Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0260","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0265","first-page":"162","article-title":"Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment","volume":"91","author":"Colombat","year":"2006","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0270","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia-Net","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0275","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJM199808273390911","article-title":"Quantifying leukemia","volume":"339","author":"Morley","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0280","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0285","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0290","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"Goh","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0300","first-page":"1677","article-title":"Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with philadelphia-positive acute lymphoblastic leukemia (ALL)","volume":"116","author":"Iacobucci","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0305","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","article-title":"In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib","volume":"116","author":"Sobrinho-Simoes","year":"2010","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0310","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0315","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/gcc.20568","article-title":"Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia","volume":"47","author":"Mattarucchi","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0320","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.1995.tb03392.x","article-title":"Characterization of genomic BCRABL breakpoints in chronic myeloid leukaemia by PCR","volume":"90","author":"Zhang","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0325","first-page":"4146","article-title":"Long-template DNA polymerase chain reaction for the detection of the bcr\/abl translocation in patients with chronic myelogenous leukemia","volume":"5","author":"Waller","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0330","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.128","article-title":"Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing","volume":"40","author":"Campbell","year":"2008","journal-title":"Nat Genet"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0335","doi-asserted-by":"crossref","first-page":"20ra14","DOI":"10.1126\/scitranslmed.3000702","article-title":"Development of personalized tumor biomarkers using massively parallel sequencing","volume":"2","author":"Leary","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0340","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0345","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/gcc.20815","article-title":"Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors","volume":"49","author":"McBride","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0350","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08645","article-title":"Complex landscapes of somatic rearrangement in human breast cancer genomes","volume":"462","author":"Stephens","year":"2009","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0355","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature08629","article-title":"A small-cell lung cancer genome with complex signatures of tobacco exposure","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0370","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nbt.1495","article-title":"The potential and challenges of nanopore sequencing","volume":"26","author":"Branton","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0375","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1373\/clinchem.2008.105916","article-title":"Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease","volume":"54","author":"Ross","year":"2008","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0380","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/sj.leu.2402730","article-title":"Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients","volume":"16","author":"Guo","year":"2002","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0385","first-page":"67","article-title":"Detection and quantification of leukemia-specific rearrangements","volume":"68","author":"Hochhaus","year":"2002","journal-title":"Methods Mol Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-0934(03)00127-7","article-title":"Single-tube nested quantitative PCR: a rational and sensitive technique for detection of retroviral DNA. Application to RERV-H\/HRV-5 and confirmation of its rabbit origin","volume":"111","author":"Forsman","year":"2003","journal-title":"J Virol Methods"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0395","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1472-765X.2009.02708.x","article-title":"A single-tube nested real-time polymerase chain reaction for sensitive contained detection of Cryptosporidium parvum","volume":"49","author":"Minarovicova","year":"2009","journal-title":"Lett Appl Microbiol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0400","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7883\/yoken.64.161","article-title":"Use of a single-tube nested real-time PCR assay to facilitate the early diagnosis of acute Q fever","volume":"64","author":"Hou","year":"2011","journal-title":"Jpn J Infect Dis"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0405","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ab.2010.10.030","article-title":"Antisense PCR: A simple and robust method for performing nested single-tube PCR","volume":"409","author":"Brisco","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0410","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assess-ment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay","volume":"131","author":"Dufresne","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0415","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2353\/jmoldx.2007.060112","article-title":"Evalua-tion of the Cepheid GeneXpert BCR-ABL assay","volume":"9","author":"Jobbagy","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0420","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0425","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","article-title":"Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?","volume":"96","author":"Cayuela","year":"2011","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0430","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/blood.V116.21.3427.3427","article-title":"Nilotinib 300 mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCR","volume":"116","author":"Conneally","year":"2010","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0435","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(94)90988-1","article-title":"Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction","volume":"343","author":"Brisco","year":"1994","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0440","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2141.1993.tb04665.x","article-title":"The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia","volume":"83","author":"Potter","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0445","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/sj.leu.2401922","article-title":"Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group","volume":"14","author":"Biondi","year":"2000","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0450","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0455","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for inter-pretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0460","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2353\/jmoldx.2009.080048","article-title":"Sensitive and specific measure-ment of minimal residual disease in acute lymphoblastic leukemia","volume":"11","author":"Morley","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0465","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/leu.2009.140","article-title":"Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis","volume":"23","author":"Bottcher","year":"2009","journal-title":"Leuke-mia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0470","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0475","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2141.2011.08681.x","article-title":"Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III\/ IV) B-cell non-Hodgkin lymphoma: a children\u2019s oncology group report","volume":"153","author":"Shiramizu","year":"2011","journal-title":"BrJ Haematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0480","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0485","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1182\/blood-2003-05-1455","volume":"102","author":"Li","year":"2003","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0490","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/sj.leu.2403234","article-title":"Acute promyelocytic leukemia: where does it stem from?","volume":"18","author":"Grimwade","year":"2004","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0495","first-page":"127","article-title":"Diagnosis and monitoring of PML-RARalpha-positive acute promyelocytic leukemia by quantitative RT-PCR","volume":"125","author":"Mokany","year":"2006","journal-title":"Methods Mol Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0500","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0505","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.leu.2402988","article-title":"WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic po-tential of WT1 targeted therapies","volume":"17","author":"Rosenfeld","year":"2003","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0510","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3109\/10428194.2010.507829","article-title":"Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia","volume":"51","author":"Miyawaki","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0515","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1620\/tjem.219.169","article-title":"WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia","volume":"219","author":"Sakamoto","year":"2009","journal-title":"Tohoku J Exp Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0520","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0525","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1399-0012.2010.01251.x","article-title":"Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leu-kemia","volume":"25","author":"Candoni","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0530","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0535","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0540","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3324\/haematol.12153","article-title":"NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia","volume":"93","author":"Falini","year":"2008","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0545","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2404637","article-title":"Clinical implications ofminimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations","volume":"21","author":"Chou","year":"2007","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0550","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc+ AML): biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0555","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prog-nostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0560","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group","volume":"29","author":"Kronke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0565","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5858\/2010-0413-RAR.1","article-title":"Molecular testing of solid tumors","volume":"135","author":"Igbokwe","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0570","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-61779-055-3_14","article-title":"Rt-PCR gene expression profiling of RNA from paraffin-embedded tissues prepared using a range of different fixatives and conditions","volume":"724","author":"Liu","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0575","first-page":"181","article-title":"Circulating nucleic acids (CNAs) and cancer \u2013 a survey","volume":"1775","author":"Fleischhacker","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0580","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2009.08.027","article-title":"Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?","volume":"43","author":"van der Vaart","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0585","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201010021","article-title":"Circulating tumor cells: approaches to isolation and characterization","volume":"192","author":"Yu","year":"2011","journal-title":"J Cell Biol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0590","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAT.0b013e3283430926","article-title":"Molecular assays in breast cancer pathology","volume":"43","author":"O\u2019Toole","year":"2011","journal-title":"Pathology"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0595","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1071\/SH10022","article-title":"Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era","volume":"7","author":"Tota","year":"2010","journal-title":"Sex Health"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0600","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0605","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0610","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","article-title":"BCR\/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability","volume":"21","author":"Skorski","year":"2002","journal-title":"Oncogene"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0615","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0620","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0625","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lympho-blastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0630","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0635","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0640","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology","volume":"11","author":"Jones","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0645","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1349-7006.2008.00727.x","article-title":"Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor","volume":"99","author":"Nishida","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0650","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0655","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0660","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0665","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0670","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection ofBCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0675","first-page":"2205","article-title":"Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells (German.)","volume":"127","author":"Muller","year":"2002","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0680","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0685","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MOH.0b013e32834399ef","article-title":"Mutational analysis in chronic myeloid leukemia: when and what to do?","volume":"18","author":"Branford","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0690","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0695","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.leukres.2008.01.010","article-title":"High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain","volume":"32","author":"Polakova","year":"2008","journal-title":"Leuk Res"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0700","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1373\/clinchem.2004.047274","article-title":"Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients","volume":"51","author":"Sorel","year":"2005","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0705","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","article-title":"Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0710","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0715","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2404635","article-title":"High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations","volume":"21","author":"Vivante","year":"2007","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0720","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00277-003-0644-y","article-title":"Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique","volume":"82","author":"Kreuzer","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0725","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/leu.2008.183","article-title":"Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR","volume":"23","author":"Oehler","year":"2009","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0730","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/leu.2008.180","article-title":"Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR","volume":"22","author":"Pelz-Ackermann","year":"2008","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0735","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1373\/clinchem.2009.133843","article-title":"Detection of drugresistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment","volume":"56","author":"Gruber","year":"2010","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0740","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"Gruber","year":"2005","journal-title":"Leukemia"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0745","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0750","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCRABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0755","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","article-title":"The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge","volume":"10","author":"Nicolini","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0760","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0765","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1373\/clinchem.2004.034801","article-title":"Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib","volume":"50","author":"Irving","year":"2004","journal-title":"Clin Chem"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0770","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0775","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib","volume":"94","author":"Ernst","year":"2009","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0780","first-page":"59","article-title":"Qualitative and quantitative DNA and RNA analysis by matrixassisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"336","author":"Ding","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0785","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0790","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronicphase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0795","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0800","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0805","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to secondor third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0810","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCRABLT315I and exhibits a narrow resistance profile","volume":"71","author":"Eide","year":"2011","journal-title":"CancerRes"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0815","series-title":"J Clin Oncol","article-title":"Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy","author":"Parker","year":"2011"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0820","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0825","series-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia","author":"O\u2019Brien","year":"2010"},{"key":"10.1097\/PAT.0b013e32834a9da8_bib0830","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exphem.2009.10.003","article-title":"Constant BCR-ABL tran-script level \u22650.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis","volume":"38","author":"Polakova","year":"2010","journal-title":"Exp Hematol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516329610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516329610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:17:22Z","timestamp":1758471442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302516329610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":166,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0031302516329610"],"URL":"https:\/\/doi.org\/10.1097\/pat.0b013e32834a9da8","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular methods in diagnosis and monitoring of haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/PAT.0b013e32834a9da8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}